HC Wainwright Reaffirms Buy Rating for VYNE Therapeutics (NASDAQ:VYNE)

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $5.75 price target on the stock. HC Wainwright’s price objective points to a potential upside of 93.60% from the stock’s previous close.

Separately, BTIG Research assumed coverage on VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 target price on the stock.

VYNE Therapeutics Stock Up 15.6 %

Shares of VYNE opened at $2.97 on Monday. The firm has a market cap of $43.81 million, a price-to-earnings ratio of -3.45 and a beta of 1.37. The company’s fifty day moving average is $2.71 and its 200-day moving average is $2.20. VYNE Therapeutics has a 12 month low of $1.57 and a 12 month high of $3.43.

Hedge Funds Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises about 0.0% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 17th largest position. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.